JonesResearch analyst Catherine Novack reiterates a Buy rating on Larimar Therapeutics (LRMR) with a $14 price target after the company reported initial data from a Phase 2 study for nomlabofusp ...

Larimar is down over 50% this year due to anaphylactic reactions in a study, rising expenses, and cautious market sentiment. Read why LRMR stock is a hold.

Larimar Therapeutics (NASDAQ:LRMR), a clinical-stage biotechnology firm focused on treatments for rare diseases such as Friedreich’s ataxia, reported its second quarter results on August 14, 2025.

BALA CYNWYD, PA — Larimar Therapeutics, Inc. (Nasdaq: LRMR) reported second-quarter 2025 results, highlighting progress toward a planned Biologics License Application (BLA) for nomlabofusp, a ...